

PROTOCOL CODE: LYCLLFBR

(Page 1 of 3)

DOCTOR'S ORDERS			Ht _____ cm	Wt _____ kg	BSA _____ m ²
REMINDER: Please ensure drug allergies and previous bleomycin are documented on the Allergy & Alert Form					
DATE:	To be given:	Cycle #:			
Date of Previous Cycle:					
<input type="checkbox"/> Delay treatment _____ week(s) <input type="checkbox"/> CBC & Diff and platelets day 1 of treatment					
Day 1: may proceed with doses as written, if within 96 hours ANC greater than or equal to 1.0 x 10⁹/L and Platelets greater than or equal to 75 x 10⁹/L					
Dose modification for: <input type="checkbox"/> Hematology <input type="checkbox"/> Other Toxicity _____ Proceed with treatment based on blood work from _____					
PREMEDICATIONS: Patient to take own supply. RN/Pharmacist to confirm _____.					
ondansetron 8 mg PO prior to bendamustine on Day 1 and Day 2 dexamethasone <input type="checkbox"/> 8 mg or <input type="checkbox"/> 12 mg (select one) PO prior to bendamustine on Day 1 and Day 2					
<u>For intravenous riTUXimab infusion:</u> diphenhydrAMINE 50 mg PO prior to riTUXimab IV and then q 4 h if IV infusion exceeds 4 h acetaminophen 650 mg to 975 mg PO prior to riTUXimab IV and then q 4 h if IV infusion exceeds 4 h					
<u>For subcutaneous riTUXimab injection:</u> diphenhydrAMINE 50 mg PO prior to riTUXimab subcut acetaminophen 650 mg to 975 mg PO prior to riTUXimab subcutaneous					
** Have Hypersensitivity Reaction Tray and Protocol Available**					
TREATMENT: Cycle 1 ONLY					
bendamustine 90 mg/m ² x BSA = _____ mg <input type="checkbox"/> Dose Modification: _____ % = _____ mg/m ² x BSA = _____ mg IV in 250 to 500 mL NS over 1 hour on Day 1 and Day 2.					
Continued on page 2					
DOCTOR'S SIGNATURE:					SIGNATURE:
					UC:

PROTOCOL CODE: LYCLLFBR

(Page 2 of 3)

DOCTOR'S ORDERS	Page 2 of 3						
DATE:							
** Have Hypersensitivity Reaction Tray and Protocol Available**							
TREATMENT: (Cycle 1 continued)							
<p>riTUXimab (first dose) 375 mg/m² x BSA = _____ mg IV in 250 to 500 mL NS on Day 1 or 2 whenever possible, but not later than 72 hours after Day 1 of bendamustine.</p> <p>Pharmacy to select riTUXimab IV brand as per Provincial Systemic Therapy Policy III-190</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 20%;">Drug</th> <th style="width: 40%;">Brand (Pharmacist to complete. Please print.)</th> <th style="width: 40%;">Pharmacist Initial and Date</th> </tr> </thead> <tbody> <tr> <td>riTUXimab</td> <td></td> <td></td> </tr> </tbody> </table> <p>Start at 50 mg/hour. After 1 hour, increase rate by 50 mg/hour every 30 minutes until rate = 400 mg/hour unless toxicity occurs.</p> <p>For the first dose, patients are to be under constant visual observation during all dose increases and for 30 minutes after infusion completed. Vital signs are not required, unless symptomatic.</p> <p>Cycle 2, 3, 4, 5 and 6</p> <p>bendamustine 90 mg/m² x BSA = _____ mg <input type="checkbox"/> Dose Modification: _____ % = _____ mg/m² x BSA = _____ mg IV in 250 to 500 mL NS over 1 hour on Day 1 and Day 2.</p> <p>riTUXimab for Cycle 2 and subsequent treatments:</p> <p><input type="checkbox"/> Patient tolerated a full dose of IV riTUXimab (no severe reactions requiring early termination) and can proceed to subcutaneous riTUXimab: riTUXimab <u>subcut</u> (RITUXAN SC) 1600 mg (fixed dose in 13.4 mL) subcutaneously into abdomen over 7 minutes. Observe for 15 minutes after administration.</p> <p>NB: During treatment with subcutaneous riTUXimab, administer other subcutaneous drugs at alternative injection sites whenever possible.</p> <p>Continued on Page 3</p>		Drug	Brand (Pharmacist to complete. Please print.)	Pharmacist Initial and Date	riTUXimab		
Drug	Brand (Pharmacist to complete. Please print.)	Pharmacist Initial and Date					
riTUXimab							
DOCTOR'S SIGNATURE:	SIGNATURE:						
	UC:						

PROTOCOL CODE: LYCLLFBR

(Page 3 of 3)

DOCTOR'S ORDERS		Page 3 of 3						
DATE:								
** Have Hypersensitivity Reaction Tray and Protocol Available**								
TREATMENT: (Cycle 2, 3, 4, 5 and 6 continued)								
<input type="checkbox"/> Patient did not tolerate a full dose of IV riTUXimab (experienced severe reactions requiring early termination) in the previous treatment and will continue with IV riTUXimab for this cycle: riTUXimab 500 mg/m ² x BSA = _____ mg IV in 250 to 500 mL NS on Day 1 or 2 whenever possible, but not later than 72 hours after Day 1 of bendamustine.								
Pharmacy to select riTUXimab IV brand as per Provincial Systemic Therapy Policy III-190								
<table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="padding: 2px;">Drug</th> <th style="padding: 2px;">Brand (Pharmacist to complete. Please print.)</th> <th style="padding: 2px;">Pharmacist Initial and Date</th> </tr> </thead> <tbody> <tr> <td style="padding: 2px;">riTUXimab</td> <td style="padding: 2px;"></td> <td style="padding: 2px;"></td> </tr> </tbody> </table>	Drug	Brand (Pharmacist to complete. Please print.)	Pharmacist Initial and Date	riTUXimab				
Drug	Brand (Pharmacist to complete. Please print.)	Pharmacist Initial and Date						
riTUXimab								
Infuse 50 mL (or 100 mL of 500 mL bag) of the dose over 30 minutes, then infuse the remaining 200 mL (or 400 mL of 500 mL bag) over 1 hour. (total infusion time = 1 hour 30 min)								
If flushing, dyspnea, rigors, rash, pruritus, vomiting, chest pain, any other new acute discomfort or exacerbation of any existing symptoms occur, stop infusion and page physician. Constant visual observation is not required.								
RETURN APPOINTMENT ORDERS								
<input type="checkbox"/> Return in four weeks for Doctor and Cycle _____. Book chemo on Day 1 and Day 2. Note: riTUXimab to be booked within 72 hours of bendamustine.								
<input type="checkbox"/> Last Cycle. Return in _____ week(s).								
CBC & Diff, platelets prior to Day 1 of each cycle <input type="checkbox"/> If clinically indicated: <input type="checkbox"/> creatinine <input type="checkbox"/> ALT <input type="checkbox"/> bilirubin <input type="checkbox"/> Other tests: <input type="checkbox"/> Consults: <input type="checkbox"/> See general orders sheet for additional requests.								
DOCTOR'S SIGNATURE:		SIGNATURE:						
		UC:						